JP2021504399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021504399A5 JP2021504399A5 JP2020529316A JP2020529316A JP2021504399A5 JP 2021504399 A5 JP2021504399 A5 JP 2021504399A5 JP 2020529316 A JP2020529316 A JP 2020529316A JP 2020529316 A JP2020529316 A JP 2020529316A JP 2021504399 A5 JP2021504399 A5 JP 2021504399A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- cancer
- composition
- amino acid
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 34
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 8
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims 8
- 125000000539 amino acid group Chemical group 0.000 claims 7
- 239000005557 antagonist Substances 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 208000035473 Communicable disease Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000012528 membrane Substances 0.000 claims 4
- 229940123237 Taxane Drugs 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 229940124060 PD-1 antagonist Drugs 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003145 cytotoxic factor Substances 0.000 claims 2
- 208000037819 metastatic cancer Diseases 0.000 claims 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 2
- 230000005937 nuclear translocation Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 102100030751 Eomesodermin homolog Human genes 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 101001064167 Homo sapiens Eomesodermin homolog Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010050017 Lung cancer metastatic Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 229940028652 abraxane Drugs 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 230000032823 cell division Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 150000002632 lipids Chemical group 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000007498 myristoylation Effects 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017904811A AU2017904811A0 (en) | 2017-11-29 | Immunopotentiating compositions and uses therefor | |
| AU2017904811 | 2017-11-29 | ||
| PCT/AU2018/051268 WO2019104381A1 (en) | 2017-11-29 | 2018-11-28 | Enhancing t-cell function and treating a t-cell dysfunctional disorder with a combination of an lsd inhibitor and a pd1 binding antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021504399A JP2021504399A (ja) | 2021-02-15 |
| JP2021504399A5 true JP2021504399A5 (https=) | 2022-01-11 |
Family
ID=66663674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020529316A Pending JP2021504399A (ja) | 2017-11-29 | 2018-11-28 | Ｌｓｄ阻害因子とｐｄ１結合アンタゴニストの組み合わせによるｔ細胞機能の増強およびｔ細胞機能障害性障害の治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210186905A1 (https=) |
| EP (1) | EP3716963A4 (https=) |
| JP (1) | JP2021504399A (https=) |
| CN (1) | CN111655247A (https=) |
| AU (1) | AU2018377852B2 (https=) |
| CA (1) | CA3083373A1 (https=) |
| SG (1) | SG11202004767TA (https=) |
| WO (1) | WO2019104381A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11542473B2 (en) | 2016-10-21 | 2023-01-03 | Amniotics Ab | Methods and compositions for generating hematopoietic cells |
| US12435128B2 (en) | 2017-05-31 | 2025-10-07 | Taiho Pharmaceutical Co., Ltd. | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 |
| EP3714883A1 (en) * | 2019-03-25 | 2020-09-30 | AC BioScience SA | Indole containing small chemical compounds and use thereof for the non-cytotoxic and immunological treatment of cancer |
| WO2020256628A1 (en) | 2019-06-20 | 2020-12-24 | Amniotics Ab | An apparatus for filtering amniotic fluid |
| CA3149964A1 (en) | 2019-09-03 | 2021-03-11 | Michelle Wykes | Methods and agents for determining patient status |
| AU2020368845A1 (en) | 2019-10-18 | 2022-05-12 | Amniotics Ab | Processes and apparatuses for obtaining amniotic mesenchymal stem cells from amniotic fluid and cells derived thereof |
| MX2022005812A (es) | 2019-11-13 | 2022-08-16 | Taiho Pharmaceutical Co Ltd | Metodos de tratamiento de enfermedades y trastornos relacionados con desmetilasa 1 especifica de lisina con inhibidores de desmetilasa 1 especifica de lisina. |
| US20220348876A1 (en) * | 2019-11-28 | 2022-11-03 | Amniotics Ab | Metabolism guides definitive lineage specification during endothelial to hematopoietic transition |
| EP4114398A1 (en) * | 2020-03-06 | 2023-01-11 | Celgene Quanticel Research, Inc. | Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc |
| WO2021195723A1 (en) * | 2020-04-03 | 2021-10-07 | The Council Of The Queensland Institute Of Medical Research | "methods for treatment of coronavirus infections" |
| CA3179176A1 (en) * | 2020-04-03 | 2021-10-07 | University Of Florida Research Foundation, Incorporated | Stem cell immunomodulatory therapy for covid-19 infection |
| EP4232163A4 (en) * | 2020-10-22 | 2024-10-30 | The Regents of University of California | MONOAMIN OXIDASE BLOCKADE THERAPY FOR THE TREATMENT OF CANCER BY REGULATION OF ANTITUMOR T-CELL IMMUNITY |
| EP4232036A4 (en) * | 2020-10-22 | 2024-10-30 | The Regents of University of California | MONOAMINE OXIDASE BLOCKADE THERAPY FOR CANCER TREATMENT BY REGULATION OF TUMOR-ASSOCIATED MACROPHAGES (TAMs) |
| US12435308B2 (en) | 2020-11-06 | 2025-10-07 | Amniotics Ab | Immunomodulation by amniotic fluid mesenchymal stem cells |
| US20250049757A1 (en) * | 2021-09-30 | 2025-02-13 | Taiho Pharmaceutical Co. Ltd. | Combinatory therapy for cancer using biphenyl compound and immune checkpoint molecule regulator |
| WO2023077188A1 (en) * | 2021-11-02 | 2023-05-11 | Epiaxis Therapeutics Pty Ltd | Proteinaceous molecules and uses therefor |
| CN117159570B (zh) * | 2023-11-01 | 2024-01-23 | 云南中医药大学 | 6-酰氧基甘露糖叠氮乙苷衍生物与氟康唑联合在制备抗耐药白念珠菌药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2958704A1 (en) * | 2014-08-25 | 2016-03-03 | University Of Canberra | Compositions for modulating cancer stem cells and uses therefor |
| EP3277689B1 (en) * | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
-
2018
- 2018-11-28 CN CN201880087971.0A patent/CN111655247A/zh active Pending
- 2018-11-28 US US16/768,578 patent/US20210186905A1/en not_active Abandoned
- 2018-11-28 SG SG11202004767TA patent/SG11202004767TA/en unknown
- 2018-11-28 CA CA3083373A patent/CA3083373A1/en active Pending
- 2018-11-28 WO PCT/AU2018/051268 patent/WO2019104381A1/en not_active Ceased
- 2018-11-28 JP JP2020529316A patent/JP2021504399A/ja active Pending
- 2018-11-28 AU AU2018377852A patent/AU2018377852B2/en active Active
- 2018-11-28 EP EP18884508.5A patent/EP3716963A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021504399A5 (https=) | ||
| Wiman | Strategies for therapeutic targeting of the p53 pathway in cancer. | |
| Duarte et al. | Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKKβ protein of the NFκB pathway | |
| Mohammed et al. | Pancreatic cancer: advances in treatment | |
| Blagosklonny et al. | Exploiting cancer cell cycling for selective protection of normal cells | |
| JP2020514321A5 (https=) | ||
| US20230218655A1 (en) | Cancer treatments | |
| JP2020518669A5 (https=) | ||
| JP2020510662A5 (https=) | ||
| JP2019513764A5 (https=) | ||
| CN102471300A (zh) | 用于增强病毒效力的组合物和方法 | |
| JP2021502423A5 (https=) | ||
| Cao et al. | Reshaping tumor immune microenvironment and modulating T cell function based on hierarchical nanotherapeutics for synergistically inhibiting osteosarcoma | |
| Martín-García et al. | The use of SP/Neurokinin-1 as a therapeutic target in colon and Rectal cancer | |
| Kossai et al. | Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy | |
| JP2008523067A5 (https=) | ||
| Liu et al. | Tissue factor promotes HCC carcinogenesis by inhibiting BCL2-dependent autophagy | |
| JP7636322B2 (ja) | 癌を処置するためのマドラシン誘導体化合物、組成物およびこれらの使用 | |
| JP6657209B2 (ja) | パニセイン化合物、その組成物及び使用 | |
| CA2409664A1 (en) | Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione | |
| Yaghoubi et al. | Anticancer activity of Helicobacter pylori ribosomal protein (HPRP) with iRGD in treatment of colon cancer | |
| JPWO2022244757A5 (https=) | ||
| US20240156800A1 (en) | Ep300 degrader and uses thereof in neuroblastoma | |
| Zaza et al. | PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosis | |
| Roychowdhury et al. | A DR4, DR5 Targeting Conjugated TRAIL Treatment for Colorectal Carcinogenesis: A Way to Future? |